目的 探討寧心寶膠囊聯(lián)合美西律治療室性早搏的臨床療效。方法 選取2022年2月—2023年11月北京市大興區(qū)人民醫(yī)院收治的室性早搏患者106例，按隨機數(shù)字表法分為對照組和治療組，每組各53例。對照組口服鹽酸美西律片，4片/次，2次/d。在對照組基礎(chǔ)上，治療組口服寧心寶膠囊，2粒/次，3次/d。兩組患者療程均為4周。觀察兩組患者臨床療效，比較治療前后兩組患者室性早搏次數(shù)、室性早搏占總心搏比例，Myerburg分級評分和36項健康調(diào)查簡表（SF-36）評分，心率變異性指標(biāo)pNN50、全部相鄰竇性R-R間期差值均方根值（rMSSD）和部竇性心搏R-R間期標(biāo)準差（SDNN），心率震蕩指標(biāo)震蕩斜率（TS）和TO，及中性粒細胞與淋巴細胞比值（NLR）和血清一氧化氮（NO）、白細胞介素-6（IL-6）水平。結(jié)果 治療后，治療組總有效率為92.45%，明顯高于對照組77.36%（P＜0.05）。治療后，兩組患者室性早搏次數(shù)及占總心搏均明顯低于同組治療前（P＜0.05），且治療后治療組明顯低于對照組（P＜0.05）。治療后，兩組Myerburg分級評分均小于治療前，而SF-36評分均高于治療前（P＜0.05），且治療后治療組患者評分明顯好于對照組（P＜0.05）。治療后，兩組pNN50、rMSSD、SDNN、TS和血清NO水平均大于同組治療前，而TO、NLR和血清IL-6濃度均低于治療前（P＜0.05），且治療后治療組這些指標(biāo)明顯好于對照組（P＜0.05）。結(jié)論 寧心寶膠囊聯(lián)合美西律治療室性早搏，療效和安全性較好，可有效穩(wěn)定病情。

Objective To explore the clinical efficacy of Ningxinbao Capsules combined with mexiletide in treatment of ventricular premature beats. Methods Patients (106 cases) with ventricular premature beats in Beijing Daxing District People's Hospital from February 2022 to November 2023 were divided into control and treatment group by random number table method, and each group had 53 cases. Patients in the control group were po administered with Mexiletine Hydrochloride Tablets, 4 tablets/time, twice daily. Patients in the treatment group were po administered with Ningxinbao Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, the number of premature ventricular contractions and the proportion of premature ventricular contractions to total heart rate, the scores of Myerburg grading and SF-36, heart rate variability and heart rate oscillation indicators pNN50, rMSSD, SDNN, TS and TO, the levels of NLR, NO and IL-6 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 92.45%, which was significantly higher than that in the control group (77.36%, P < 0.05). After treatment, the number of ventricular premature beats and their proportion to total heart beats in two groups were significantly lower than before treatment in the same group (P < 0.05), and which in the treatment group were significantly lower than the control group (P < 0.05). After treatment, the Myerburg grading scores in two groups were lower than before treatment, while the SF-36 scores were higher than before treatment (P < 0.05), and the scores in the treatment group were significantly better than those in the control group after treatment (P < 0.05). After treatment, the pNN50, rMSSD, SDNN, TS and serum NO levels in two groups were higher than those in the same group before treatment, while the TO, NLR and serum IL-6 levels were lower (P < 0.05), and after treatment these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The combination of Ningxinbao Capsules and mexiletide is effective and safe in the treatment of ventricular premature beats. It can effectively stabilize the condition.

R972